[COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of december 18, 2021].

Gregory P Arutyunov Alexander V Amelin I A Voznjouk A A Kulesh M Yu Maksimova V R Mkrtchyan M V Putilina V A Sorokoumov A V Fonyakin Dina R Khasanova

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)

The resolution of the Council of Experts devoted to the discussion of the effectiveness of the use of a combination of rivaroxaban 2.5 mg 2 times a day and acetylsalicylic acid 100 mg per day to prevent recurrent non-coronary ischemic stroke results of the COMPASS study is presented. The advantages of this combination and the safety of its use are considered. Recommendations for the implementation of the results of the study in clinical practice are given.

Keyphrases

clinical practice
randomized controlled trial
atrial fibrillation
primary care
healthcare
systematic review
heart failure
pulmonary embolism
coronary artery disease
end stage renal disease
venous thromboembolism
quality improvement
prognostic factors
blood brain barrier